Podlipnik, S. (S.)

Filtering

2019 - 201912020 - 20211

Settings

Author search.filters.isAuthorOfPublication.4d80ca7e-7795-4ee8-b7b6-d4756e99d15a

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study
    (Wiley, 2019) Boada, A. (Aram); Carrera, C. (Cristina); Elosua-Gonzalez, M. (M.); MartÍn-Gonzalez, M.M. (M. M.); Puig, S. (Susana); Moreno, E. (Edgardo); Lopez-Estebaranz, J.L. (J. L.); Redondo-Bellón, P. (Pedro); Pinedo-Moraleda, F. (F.); Richarz, N.A. (N. A.); Podlipnik, S. (S.); Malvehy, J. (J.); Carrillo-Gijon, R. (R.)
    Background: The clinical and pathological features of primary melanoma are not sufficiently sensitive to accurately predict which patients are at a greater risk of relapse. Recently, a 31-gene expression profile (DecisionDx-Melanoma) test has shown promising results. Objectives: To evaluate the early prognostic performance of a genetic signature in a multicentre prospectively evaluated cohort. Methods: Inclusion of patients with AJCC stages IB and II conducted between April 2015 and December 2016. All patients were followed up prospectively to assess their risk of relapse. Prognostic performance of this test was evaluated individually and later combined with the AJCC staging system. Prognostic accuracy of disease-free survival was determined using Kaplan-Meier curves and Cox regression analysis. Results of the gene expression profile test were designated as Class 1 (low risk) and Class 2 (high risk). Results: Median follow-up time was 26 months (IQR 22-30). The gene expression profile test was performed with 86 patients; seven had developed metastasis (8.1%) and all of them were in the Class 2 group, representing 21.2% of this group. Gene expression profile was an independent prognostic factor for relapse as indicated by multivariate Cox regression analysis, adjusted for AJCC stages and age. Conclusions: This prospective multicentre cohort study, performed in a Spanish Caucasian cohort, shows that this 31-gene expression profile test could correctly identify patients at early AJCC stages who are at greater risk of relapse. We believe that gene expression profile in combination with the AJCC staging system could well improve the detection of patients who need intensive surveillance and optimize follow-up strategies.
  • Thumbnail Image
    Effects of COVID-19 lockdown on tumour burden of melanoma and cutaneous squamous cell carcinoma
    (Medical Journals Sweden AB, 2021) Tejera-Vaquerizo, A. (Antonio); Paradela, S. (Sabela); Toll-Abelló, A. (Agustí); Santos-Juanes, J. (Jorge); Jaka, A. (Ane); López, A. (Alba); Cañueto, J. (Javier); Bernal, A. (Alvaro); Villegas-Romero, I. (Isabel); Ferrándiz-Pulido, C. (C.); Perandones, H. (Héctor); Moreno-Ramírez, D. (David); Domínguez-Mahamud, C. (Carolina); Salido-Vallejo, R. (Rafael); Sanmartin-Jiménez, O. (Onofre); Rodríguez-Jiménez, P. (Pedro); Bañuls, J. (José); Podlipnik, S. (S.); Sandoval-Clavijo, A. (Alejandra); Boada, A. (Aram); García-Bracamonte, B. (Beatriz); Palencia, S. (Sara); Revilla-Nevreda, D. (David); Reola-Ramírez, E. (Enara); Gómez-Mateo, M.C. (María del Carmen); Linares-Barrios, M. (Mario); Jiménez, D. (David); González-Cruz, C. (Carlos); Samaniego, E. (Elia); Navedo-de-las-Heras, M. (María)
    The aim of this study was to compare tumour burden in patients who underwent surgery for melanoma and cutaneous squamous cell carcinoma during nationwide lockdown in Spain due to COVID-19 (for the period 14 March to 13 June 2020) and during the same dates in 2019 before the COVID-19 pandemic. In addition, associations between median tumour burden (Breslow thickness for melanoma and maximum clinical diameter for cutaneous squamous cell carcinoma) and demographic, clinical, and medical factors were analysed, building a multivariate linear regression model. During the 3 months of lockdown, there was a significant decrease in skin tumours operated on (41% decrease for melanoma (n = 352 vs n = 207) and 44% decrease for cutaneous squamous cell carcinoma (n = 770 vs n = 429)) compared with the previous year. The proportion of large skin tumours operated on increased. Fear of SARS-CoV-2 infection, with respect to family member/close contact, and detection of the lesion by the patient or doctor, were related to thicker melanomas; and fear of being diagnosed with cancer, and detection of the lesion by the patient or relatives, were related to larger size cutaneous squamous cell carcinoma. In conclusion, lockdown due to COVID-19 has resulted in a reduction in treatment of skin cancer.